1
|
Rutherford S, Gaschen F, Husnik R, Fletcher J, Gaschen L. Ultrasonographic evaluation of the effects of azithromycin on antral motility and gastric emptying in healthy cats. J Vet Intern Med 2022; 36:508-514. [PMID: 35150012 PMCID: PMC8965205 DOI: 10.1111/jvim.16385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 01/29/2022] [Accepted: 02/01/2022] [Indexed: 11/29/2022] Open
Abstract
Background Erythromycin, a macrolide antibiotic with motilin agonist properties, shortens gastric emptying (GE) time in healthy cats. Azithromycin, another macrolide antibiotic, is effective for treatment of gastric paresis in people. Objectives To evaluate the effects of azithromycin on GE and gastric motility in healthy cats in comparison with erythromycin (positive control) and placebo. Animals Eight healthy purpose‐bred cats. Methods Prospective, blinded, crossover study. Cats received either azithromycin (3.5 mg/kg PO q24h), erythromycin (1 mg/kg PO q8h), or placebo for 24 hours before and during evaluation of GE. A validated method using ultrasound for sequential measurements of antral area as well as amplitude and frequency of contractions was used to assess GE and evaluate gastric antral motility postprandially over an 8‐hour period. Results GE was significantly faster (P < .05) after administration of azithromycin and erythromycin when compared to placebo in the late phase of fractional emptying from 75% (mean ± SD: 327 ± 51 minutes, 327 ± 22 minutes, and 367 ± 29 minutes, respectively), to 95% fractional emptying (399 ± 52 minutes, 404 ± 11 minutes, and 444 ± 24 minutes, respectively). The drugs had no significant effect on antral motility variables at any time point. Conclusions and Clinical Importance Azithromycin and erythromycin shorten GE time in a comparable manner in healthy cats. Evaluation of their efficacy in cats with gastric dysmotility is warranted.
Collapse
Affiliation(s)
- Stephanie Rutherford
- Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Frederic Gaschen
- Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Roman Husnik
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, Indiana, USA
| | | | - Lorrie Gaschen
- Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA
| |
Collapse
|
2
|
Mechery S, Narayanan Nair S, Divya TM, Promod K, Paramba SIN, Ravindran R, Juliet S. Influence of Pyrexia on Pharmacokinetics of Azithromycin and Its Interaction With Tolfenamic Acid in Goats. Front Vet Sci 2021; 8:675603. [PMID: 34179168 PMCID: PMC8222727 DOI: 10.3389/fvets.2021.675603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Accepted: 04/27/2021] [Indexed: 11/13/2022] Open
Abstract
Azithromycin is a macrolide antimicrobial agent of the azalide group with a broad spectrum of activity against gram-negative and gram-positive bacterial organisms. Tolfenamic acid is a non-steroidal anti-inflammatory drug of the fenamate group, which is used extensively in humans and animals due to its anti-inflammatory, analgesic, and antipyretic properties. There is dearth of literature on any type of drug interaction between azithromycin and tolfenamic acid in any species, including human beings and alteration of its pharmacokinetics by fever. Therefore, the objective of this study was to investigate the alteration of disposition kinetics of azithromycin alone and in the presence of tolfenamic acid in Malabari goats by fever, following an intravenous administration at a dose rate of 20 mg/kg body weight. Blood samples collected from both afebrile and febrile goats at predetermined time intervals after the administration of azithromycin alone and then in combination with tolfenamic acid (2 mg/kg, intravenously), respectively, were analyzed using high-performance liquid chromatography. Non-compartmental analysis was used to determine the peak blood concentration (C max), time-to-peak plasma concentration (T max), half-life (t 1/2λz ), area under the curve (AUC 0-t, AUC 0-inf), area under the first moment curve (AUMC 0-inf), mean residence time (MRT0-inf), apparent volume of distribution at steady state (V ss), and the total body clearance of drug from the blood (Cl). In febrile animals, significant differences were noted in the values of C max, Cl, and V ss. Thus, azithromycin disappears into an additional compartment in febrile goats, which may be due to its extended cellular penetration into the inflammatory cells, resulting in anti-inflammatory activity. Tolfenamic acid significantly altered the pharmacokinetics of azithromycin in both normal and febrile animals. Tolfenamic acid, being a better anti-inflammatory agent, suppresses the inflammatory mediators, reducing the possibility of increased utilization of azithromycin in febrile condition.
Collapse
Affiliation(s)
- Sini Mechery
- Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| | - Suresh Narayanan Nair
- Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| | - Thirumangalath Meethal Divya
- Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| | - Kanjirakuzhiyil Promod
- Department of Animal Reproduction Obstetrics and Gynaecology, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| | - Sakkariya Ibrahim Nalukudy Paramba
- Department of Livestock Production Management, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| | - Reghu Ravindran
- Department of Veterinary Parasitology, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| | - Sanis Juliet
- Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Wayanad, India
| |
Collapse
|
3
|
Sherazi STH, Mahesar SA, Sirajuddin, Malah MA. Brief Overview of Frequently used Macrolides and Analytical Techniques for their Assessment. CURR ANAL CHEM 2019. [DOI: 10.2174/1573411014666180917105750] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background:
Macrolide antibiotics are known as versatile broad-spectrum antibiotics.
Macrolides belong to the oldest group of antibacterial agents. The macrolides which are frequently
used for clinical purposes are broadly categorized in three classes depending on the number of
membered macrocyclic lactone ring. These three classes actually consist of 14, 15 or 16 atoms in macrocyclic
lactone ring which are linked through glycosidic bonds. Erythromycin, azithromycin clarithromycin
and roxithromycin are frequently used to control against bacterial infections.
Methods:
The quality assurance and quality controls are important tasks in the pharmaceutical industries.
Consequently, to check the quality of drugs, there is a strong need to know about alternative
analytical methods for the routine analysis. Many methods have been reported in the literature for the
quantitative determination of erythromycin, clarithromycin, azithromycin and clarithromycin in
pharmaceutical formulations and biological samples.
Results:
This review will cover a brief introduction of erythromycin, azithromycin, clarithromycin and
roxithromycin as well as analytical techniques for their assessment. Each developed method has its
own merits and demerits.
Conclusion:
Any accurate method could be used for the quality control and quality assurance of
macrolide antibiotics according to the availability, performance and procedure of selected instrument
as well as skill and expertise of the analyst.
Collapse
Affiliation(s)
| | - Sarfaraz Ahmed Mahesar
- National Centre of Excellence in Analytical Chemistry, University of Sindh, Jamshoro-76080, Pakistan
| | - Sirajuddin
- National Centre of Excellence in Analytical Chemistry, University of Sindh, Jamshoro-76080, Pakistan
| | - Muhammad Ali Malah
- National Centre of Excellence in Analytical Chemistry, University of Sindh, Jamshoro-76080, Pakistan
| |
Collapse
|
4
|
Whittemore JC, Stokes JE, Laia NL, Price JM, Suchodolski JS. Short and long-term effects of a synbiotic on clinical signs, the fecal microbiome, and metabolomic profiles in healthy research cats receiving clindamycin: a randomized, controlled trial. PeerJ 2018; 6:e5130. [PMID: 30038854 PMCID: PMC6054061 DOI: 10.7717/peerj.5130] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Accepted: 06/08/2018] [Indexed: 12/18/2022] Open
Abstract
Background Antibiotic-associated gastrointestinal signs (AAGS) occur commonly in cats. Co-administration of synbiotics is associated with decreased AAGS in people, potentially due to stabilization of the fecal microbiome and metabolome. The purpose of this double-blinded randomized-controlled trial was to compare AAGS and the fecal microbiome and metabolome between healthy cats that received clindamycin with a placebo or synbiotic. Methods 16 healthy domestic shorthair cats from a research colony were randomized to receive 150 mg clindamycin with either a placebo (eight cats) or commercially-available synbiotic (eight cats) once daily for 21 days with reevaluation 603 days thereafter. All cats ate the same diet. Food consumption, vomiting, and fecal score were recorded. Fecal samples were collected daily on the last three days of baseline (days 5–7), treatment (26–28), and recovery (631–633). Sequencing of 16S rRNA genes and gas chromatography time-of-flight mass spectrometry was performed. Clinical signs, alpha and beta diversity metrics, dysbiosis indices, proportions of bacteria groups, and metabolite profiles were compared between treatment groups using repeated measures ANOVAs. Fecal metabolite pathway analysis was performed. P < 0.05 was considered significant. The Benjamini & Hochberg’s False Discovery Rate was used to adjust for multiple comparisons. Results Median age was six and five years, respectively, for cats in the placebo and synbiotic groups. Hyporexia, vomiting, diarrhea, or some combination therein were induced in all cats. Though vomiting was less in cats receiving a synbiotic, the difference was not statistically significant. Bacterial diversity decreased significantly on days 26–28 in both treatment groups. Decreases in Actinobacteria (Bifidobacterium, Collinsella, Slackia), Bacteriodetes (Bacteroides), Lachnospiraceae (Blautia, Coprococcus, Roseburia), Ruminococcaceae (Faecilobacterium, Ruminococcus), and Erysipelotrichaceae (Bulleidia, [Eubacterium]) and increases in Clostridiaceae (Clostridium) and Proteobacteria (Aeromonadales, Enterobacteriaceae) occurred in both treatment groups, with incomplete normalization by days 631–633. Derangements in short-chain fatty acid, bile acid, indole, sphingolipid, benzoic acid, cinnaminic acid, and polyamine profiles also occurred, some of which persisted through the terminal sampling timepoint and differed between treatment groups. Discussion Cats administered clindamycin commonly develop AAGS, as well as short- and long-term dysbiosis and alterations in fecal metabolites. Despite a lack of differences in clinical signs between treatment groups, significant differences in their fecal metabolomic profiles were identified. Further investigation is warranted to determine whether antibiotic-induced dysbiosis is associated with an increased risk of future AAGS or metabolic diseases in cats and whether synbiotic administration ameliorates this risk.
Collapse
Affiliation(s)
- Jacqueline C Whittemore
- Department of Small Animal Clinical Sciences, University of Tennessee-Knoxville, Knoxville, TN, United States of America
| | - Jennifer E Stokes
- Department of Small Animal Clinical Sciences, University of Tennessee-Knoxville, Knoxville, TN, United States of America
| | - Nicole L Laia
- Department of Small Animal Clinical Sciences, University of Tennessee-Knoxville, Knoxville, TN, United States of America
| | - Joshua M Price
- Office of Information Technology, University of Tennessee-Knoxville, Knoxville, TN, United States of America
| | - Jan S Suchodolski
- The Gastrointestinal Laboratory, Small Animal Clinical Sciences, Texas A&M University, College Station, TX, United States of America
| |
Collapse
|
5
|
Stokes JE, Price JM, Whittemore JC. Randomized, Controlled, Crossover trial of Prevention of Clindamycin-Induced Gastrointestinal Signs Using a Synbiotic in Healthy Research Cats. J Vet Intern Med 2017; 31:1406-1413. [PMID: 28755457 PMCID: PMC5598878 DOI: 10.1111/jvim.14795] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 05/11/2017] [Accepted: 06/27/2017] [Indexed: 12/23/2022] Open
Abstract
Background Synbiotics often are prescribed to limit antibiotic‐associated gastrointestinal signs (AAGS) in cats, but data to support this recommendation are lacking. Objective To determine whether synbiotic co‐administration mitigates AAGS in healthy research cats treated with clindamycin. Animals 16 healthy research cats. Methods A randomized, double‐blinded, placebo‐controlled, 2‐way, 2‐period, crossover study with a 6‐week washout was performed. Each study period consisted of a 1‐week baseline and a 3‐week treatment period. Cats received 75 mg clindamycin with food once daily for 3 weeks, followed 1 hour later by either 2 capsules of a synbiotic or placebo. Food consumption, vomiting, fecal score, and completion of treatment were compared using repeated measures split plot or crossover designs with covariates, with P < 0.05 considered significant. Results Cats that received the synbiotic were more likely to complete treatment in period 1 (100% vs. 50%, P = 0.04). Cats vomited less when receiving the synbiotic but this was not significant, but there were significant period effects (F‐value = 11.4, P < 0.01). Cats had higher food intake while receiving the synbiotic (F‐value = 31.1, P < 0.01) despite period effects (F‐value = 8.6, P < 0.01). There was no significant effect of treatment on fecal scores, which significantly increased over time (F‐value = 17.9, P < 0.01). Conclusions and Clinical Importance Administration of a synbiotic 1 hour after clindamycin administration decreased hyporexia and vomiting in healthy cats. Additionally, significant period effects suggest that clinical benefits of synbiotic administration persist for at least 6 weeks after discontinuation, decreasing the severity of AAGS in cats that subsequently received clindamycin with placebo. Unlike in people, synbiotic administration did not decrease antibiotic‐associated diarrhea.
Collapse
Affiliation(s)
- J E Stokes
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN
| | - J M Price
- Office of Information Technology, University of Tennessee, Knoxville, TN
| | - J C Whittemore
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN
| |
Collapse
|
6
|
Lappin M, Blondeau J, Boothe D, Breitschwerdt E, Guardabassi L, Lloyd D, Papich M, Rankin S, Sykes J, Turnidge J, Weese J. Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases. J Vet Intern Med 2017; 31:279-294. [PMID: 28185306 PMCID: PMC5354050 DOI: 10.1111/jvim.14627] [Citation(s) in RCA: 146] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2016] [Revised: 09/05/2016] [Accepted: 11/07/2016] [Indexed: 12/21/2022] Open
Abstract
Respiratory tract disease can be associated with primary or secondary bacterial infections in dogs and cats and is a common reason for use and potential misuse, improper use, and overuse of antimicrobials. There is a lack of comprehensive treatment guidelines such as those that are available for human medicine. Accordingly, the International Society for Companion Animal Infectious Diseases convened a Working Group of clinical microbiologists, pharmacologists, and internists to share experiences, examine scientific data, review clinical trials, and develop these guidelines to assist veterinarians in making antimicrobial treatment choices for use in the management of bacterial respiratory diseases in dogs and cats.
Collapse
Affiliation(s)
- M.R. Lappin
- Colorado State UniversityFort CollinsCODenmark
| | | | | | | | | | | | - M.G. Papich
- North Carolina State UniversityRaleighNCDenmark
| | - S.C. Rankin
- University of PennsylvaniaPhiladelphiaPAAustralia
| | - J.E. Sykes
- University of CaliforniaDavisCAAustralia
| | - J. Turnidge
- The Women's and Children HospitalAdelaideSA,Australia
| | - J.S. Weese
- Ontario Veterinary CollegeGuelphONAustralia
| |
Collapse
|
7
|
Azithromycin pharmacokinetics in the serum and its distribution to the skin in healthy dogs and dogs with pyoderma. Vet J 2014; 200:122-6. [PMID: 24472431 DOI: 10.1016/j.tvjl.2013.12.022] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2013] [Revised: 12/29/2013] [Accepted: 12/31/2013] [Indexed: 11/20/2022]
Abstract
Serum and skin tissue azithromycin (AZM) concentrations were analysed in healthy and pyoderma affected dogs to determine AZM pharmacokinetics and to establish the effect of disease on AZM skin disposition. AZM was administered orally to two groups of healthy dogs: (1) at 7.02 mg/kg (n=7) and (2) at 11.2mg/kg (n=9). A crossover design was used on five of them. Seven dogs with pyoderma were treated with AZM at 10.7 mg/kg. The two groups of healthy dogs received AZM once daily over three consecutive days and dogs with pyoderma received the same treatment repeated twice with an interval of 1 week. AZM concentrations were determined by liquid chromatography-tandem mass spectrometry. AZM was rapidly absorbed and slowly excreted. In healthy dogs, maximum serum concentrations appeared 2h after administration and were (mean ± standard deviation) 0.60 ± 0.25 μg/mL and 1.03 ± 0.43 μg/mL, and the half-lives were 49.9 ± 5.10 and 51.9 ± 6.69 h for doses of 7.02 and 11.2mg/kg, respectively. Clearance (CL0-24/F) was similar in both dosing groups (1.24 ± 0.24 and 1.29 ± 0.24 L/h/kg) and the respective mean residence time (MRT0-24) was 11.1 ± 0.8 and 8.4 ± 2.2h. The skin concentration in healthy dogs was 3.5-6.5 and 5.0-12.0 times higher than the corresponding serum concentration after the two doses and increased after the cessation of AZM administration. The ratio increased significantly in inflamed tissue (9.5-26.2).
Collapse
|
8
|
Albarellos GA, Montoya L, Landoni MF. Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats. Vet J 2009; 187:129-32. [PMID: 19854664 DOI: 10.1016/j.tvjl.2009.09.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Revised: 08/13/2009] [Accepted: 09/20/2009] [Indexed: 10/20/2022]
Abstract
The aim of this study was to characterise the pharmacokinetic properties of different formulations of erythromycin in cats. Erythromycin was administered as lactobionate (4 mg/kg intravenously (IV)), base (10mg/kg, intramuscularly (IM)) and ethylsuccinate tablets or suspension (15 mg/kg orally (PO)). After IV administration, the major pharmacokinetic parameters were (mean ± SD): area under the curve (AUC)((0-∞)) 2.61 ± 1.52 microgh/mL; volume of distribution (V(z)) 2.34 ± 1.76L/kg; total body clearance (Cl(t)) 2.1 0 ± 1.37 L/hkg; elimination half-life (t(½)(λ)) 0.75 ± 0.09 h and mean residence time (MRT) 0.88 ± 0.13 h. After IM administration, the principal pharmacokinetic parameters were (mean ± DS): peak concentration (C(max)), 3.54 ± 2.16 microg/mL; time of peak (T(max)), 1.22 ± 0.67 h; t(½)(λ), 1.94 ± 0.21 h and MRT, 3.50 ± 0.82 h. The administration of erythromycin ethylsuccinate (tablets and suspension) did not result in measurable serum concentrations. After IM and IV administrations, erythromycin serum concentrations were above minimum inhibitory concentration (MIC)(90)=0.5 microg/mL for 7 and 1.5h, respectively. However, these results should be interpreted cautiously since tissue erythromycin concentrations have not been measured and can reach much higher concentrations than in blood, which may be associated with enhanced clinical efficacy.
Collapse
Affiliation(s)
- G A Albarellos
- Cátedra de Farmacología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Chorroarín 280 (1427), Buenos Aires, Argentina.
| | | | | |
Collapse
|
9
|
Albarellos G, Landoni M. Current concepts on the use of antimicrobials in cats. Vet J 2009; 180:304-16. [DOI: 10.1016/j.tvjl.2008.01.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2007] [Revised: 12/21/2007] [Accepted: 01/04/2008] [Indexed: 11/30/2022]
|
10
|
Ruch-Gallie RA, Veir JK, Spindel ME, Lappin MR. Efficacy of amoxycillin and azithromycin for the empirical treatment of shelter cats with suspected bacterial upper respiratory infections. J Feline Med Surg 2008; 10:542-50. [DOI: 10.1016/j.jfms.2008.04.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/01/2008] [Indexed: 11/26/2022]
Abstract
Thirty-one cats showing clinical signs of upper respiratory tract disease with a presumed bacterial component based on clinical signs were administered either amoxycillin or azithromycin to determine which drug protocol was optimal for empirical use. A clinical score was determined and nasal and pharyngeal swabs were collected for bacterial culture, virus isolation and polymerase chain reaction prior to the start of therapy. Cats failing to respond to the initial antibiotic were then administered the other drug. There were no differences in clinical scores between the two groups at the start of therapy. Eleven of 31 cats improved after administration of the first antibiotic, 16 cats were switched to the alternate antibiotic, and four cats were removed from the study for additional supportive treatments. Eight of 27 cats failed to respond to either antibiotic. The χ2 test for outcomes revealed no differences in response to therapy for either antimicrobial.
Collapse
Affiliation(s)
- Rebecca A. Ruch-Gallie
- College of Veterinary Medicine and
Biomedical Sciences, Colorado State University, Campus Delivery 162, Fort Collins, CO 80523,
United States
| | - Julia K. Veir
- College of Veterinary Medicine and
Biomedical Sciences, Colorado State University, Campus Delivery 162, Fort Collins, CO 80523,
United States
| | - Miranda E. Spindel
- College of Veterinary Medicine and
Biomedical Sciences, Colorado State University, Campus Delivery 162, Fort Collins, CO 80523,
United States
| | - Michael R. Lappin
- College of Veterinary Medicine and
Biomedical Sciences, Colorado State University, Campus Delivery 162, Fort Collins, CO 80523,
United States
| |
Collapse
|
11
|
Spindel ME, Veir JK, Radecki SV, Lappin MR. Evaluation of pradofloxacin for the treatment of feline rhinitis. J Feline Med Surg 2008; 10:472-9. [PMID: 18619887 DOI: 10.1016/j.jfms.2008.04.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/21/2008] [Indexed: 10/21/2022]
Abstract
Forty humane society cats with suspected bacterial upper respiratory infections (URIs) were studied in order to compare amoxycillin and pradofloxacin for treatment of rhinitis and describe common pathogens. Nasal discharges were collected prior to random placement into one of three treatment groups. Cats failing to initially respond were crossed to the alternate drug. Drug toxicity was not noted. The organisms most frequently isolated or amplified pre-treatment were feline herpesvirus-1 (75%), Mycoplasma species (62.5%), Bordetella species (47.5%), Staphylococcus species (12.5%) and Streptococcus species (10.0%). No differences in clinical scores between groups over time were noted. Overall response rates for amoxycillin at 22 mg/kg, q12 h for seven doses (10/15 cats; 67%), pradofloxacin at 5 mg/kg, q24 h for seven doses (11/13 cats; 85%), and pradofloxacin at 10 mg/kg, q24 h for seven doses (11/12 cats; 92%) were not statistically significant. Results suggest that pradofloxacin can be a safe, efficacious therapy for some cats with suspected bacterial URI.
Collapse
Affiliation(s)
- Miranda E. Spindel
- Department of Clinical Sciences, Colorado State University, 300 West Drake, Fort Collins, CO, United States
| | - Julia K. Veir
- Department of Clinical Sciences, Colorado State University, 300 West Drake, Fort Collins, CO, United States
| | - Steven V. Radecki
- Department of Clinical Sciences, Colorado State University, 300 West Drake, Fort Collins, CO, United States
| | - Michael R. Lappin
- Department of Clinical Sciences, Colorado State University, 300 West Drake, Fort Collins, CO, United States
| |
Collapse
|
12
|
|
13
|
Abstract
Effective respiratory therapy depends on obtaining a definitive diagnosis and following established recommendations for treatment. Unfortunately, many respiratory conditions are idiopathic in origin or are attributable to nonspecific inflammation. In some situations, disorders are controlled rather than cured. Recent advances in pulmonary therapeutics include the use of new agents to treat common diseases and application of local delivery of drugs to enhance drug effect and minimize side effects.
Collapse
Affiliation(s)
- Elizabeth A Rozanski
- Section of Critical Care, Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.
| | | | | |
Collapse
|
14
|
Carpenter JW, Olsen JH, Randle-Port M, Koch DE, Isaza R, Hunter RP. Pharmacokinetics of azithromycin in the blue and gold macaw (Ara ararauna) after intravenous and oral administration. J Zoo Wildl Med 2007; 36:606-9. [PMID: 17312716 DOI: 10.1638/04106.1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Azithromycin is classified as an azalide, a subclass of macrolide antimicrobials with a broad spectrum of activity in vitro against many potential bacterial pathogens including spirochetes, anaerobes, and Chlamydia trachomatis. Because of limited data on the use of azithromycin in avian medicine, this study was designed to determine the pharmacokinetics of azithromycin in blue and gold macaws (Ara ararauna), a species commonly seen in clinical practice. Azithromycin (10 mg/kg) was administered via crop lavage to five birds and intravenously to five birds, and blood samples were obtained at 0, 0.5, 1, 3, 6, 12, 24, 48, 72, and 96 hr post-azithromycin administration. Following a 4-wk washout period, the study was repeated with a complete crossover study performed. Concentration of azithromycin in plasma samples was quantified using a validated liquid chromatography/mass spectrometry assay. Pharmacokinetic parameters were determined using noncompartmental analysis. Based on the pharmacokinetic data generated from this study, a starting dose of azithromycin at 10 mg/kg p.o. every 48 hr for susceptible bacterial infections in blue and gold macaws is recommended.
Collapse
Affiliation(s)
- James W Carpenter
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506, USA
| | | | | | | | | | | |
Collapse
|
15
|
Cárceles CM, Fernández-Varón E, Marín P, Escudero E. Tissue disposition of azithromycin after intravenous and intramuscular administration to rabbits. Vet J 2006; 174:154-9. [PMID: 16904354 DOI: 10.1016/j.tvjl.2006.05.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2006] [Revised: 05/10/2006] [Accepted: 05/12/2006] [Indexed: 11/21/2022]
Abstract
Tissue disposition of azithromycin after intravenous (IV) or intramuscular (IM) injection at a single dose rate of 10mg/kg bodyweight were investigated in rabbits using a modified agar diffusion bioassay for determining tissue concentrations. The pharmacokinetic behaviour of azithromycin was characterized by low and sustained plasma concentrations but high and persistent tissue concentrations. Kinetic parameters indicated a high retention of the drug in peripheral compartments. The plasma half-lives after IV and IM administrations were similar being 21.8h and 23.1h, respectively, while the half-lives obtained in tissues after IV and IM administration were at least 1.4 and 1.9 times longer than in plasma, respectively. The highest tissue concentrations were found in bile, liver and spleen whereas the lowest ones were found in skeletal muscle (although they were higher than those in plasma). From the results of the single administration in this study an IM dosage regimen can be proposed that achieves minimum concentrations over 2mg/L in rabbits: three doses of 4-5mg/kg/day would provide suitable therapeutic concentrations in pulmonary tissues over seven days.
Collapse
Affiliation(s)
- Carlos M Cárceles
- Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Campus de Espinardo, Murcia, 30.071 Espinardo, Spain
| | | | | | | |
Collapse
|
16
|
Escudero E, Fernández-Varón E, Marín P, Espuny A, Nájera MD, Cárceles CM. Pharmacokinetics and tissue tolerance of azithromycin after intramuscular administration to rabbits. Res Vet Sci 2006; 81:366-72. [PMID: 16530237 DOI: 10.1016/j.rvsc.2006.01.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2005] [Revised: 01/30/2006] [Accepted: 01/30/2006] [Indexed: 11/24/2022]
Abstract
The pharmacokinetics of azithromycin after intravenous and intramuscular injection at a single dose rate of 10mg/kg bodyweight were investigated in rabbits by using a modified agar diffusion bioassay for determining plasma concentrations. The plasma creatine kinase activity was determined after i.m. administration for the evaluation of the tissue tolerance. The elimination half-lives of azithromycin after intravenous and intramuscular administration were 24.1 and 25.1h, respectively. After intramuscular administration mean peak plasma concentration was 0.26+/-0.01 mg/L and bioavailability was 97.7%. Plasma CK activity rose sharply within 8h after i.m. injection of azithromycin; activity returned to pre-treatment level by 48-72 h post-treatment. The transient rise in serum CK activity indicates some degree of muscle tissue damage at the injection site.
Collapse
Affiliation(s)
- E Escudero
- Departamento de Farmacología, Facultad de Veterinaria, Universidad de Murcia, Campus de Espinardo, 30071 Murcia, Spain.
| | | | | | | | | | | |
Collapse
|
17
|
Cárceles CM, Font A, Escudero E, Espuny A, Marín P, Fernández-Varón E. Pharmacokinetics of azithromycin after i.v. and i.m. administration to sheep. J Vet Pharmacol Ther 2005; 28:475-9. [PMID: 16207311 DOI: 10.1111/j.1365-2885.2005.00680.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The pharmacokinetics (PK) of azithromycin after i.v. and i.m. injection at a single dosage of 20 mg/kg bodyweight was studied in sheep. Blood samples were collected from the jugular vein until 120 h after dosing for both routes. Plasma concentrations of azithromycin were determined by bioassay. The plasma concentration-time data of azithromycin best fitted a three-compartment model after i.v. administration and a two-compartment model with first-order absorption after i.m. administration. The elimination half-life (t(1/2lambdaz)) was 47.70 +/- 7.49 h after i.v. administration and 61.29 +/- 13.86 h after i.m. administration. Clearance value after i.v. dosing was 0.52 +/- 0.08 L/kg.h. After i.m. administration a peak azithromycin concentration (C(max)) of 1.26 +/- 0.19 mg/L was achieved at 1.24 +/- 0.31 h (t(max)). Area under the curve (AUC) were 38.85 +/- 5.83 mg.h/L and 36.03 +/- 1.52 mg.h/L after i.v. and i.m. administration respectively. Bioavailability obtained after i.m. administration was 94.08 +/- 11.56%. The high tolerability of this i.m. preparation and the favourable PK behaviour such as the long half-life and high bioavailability make azithromycin likely to be effective in sheep.
Collapse
Affiliation(s)
- C M Cárceles
- Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Campus de Espinardo, Murcia, Spain
| | | | | | | | | | | |
Collapse
|
18
|
Heeb HL, Chun R, Koch DE, Moore L, Radlinsky M, Corse M, Pellerin MA, Garrett L, Hunter RP. Multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine in the cat. J Vet Pharmacol Ther 2005; 28:447-52. [PMID: 16207307 DOI: 10.1111/j.1365-2885.2005.00682.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The purpose of this study was to evaluate the multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine alone and in combination in cats. Seven healthy cats were included in this randomized-crossover study. The cats were assigned to groups designated to receive cimetidine alone (15 mg/kg, p.o., q12 h), piroxicam alone (0.3 mg/kg, p.o., q24 h), and piroxicam combined with cimetidine (both at aforementioned doses). The cats were dosed for 10 days followed by at least a 2-week washout period between trials. Serial blood samples were collected following the first and last doses and analyzed utilizing a high-performance liquid chromatography with mass spectrometry detection (LC/MS) assay. Pharmacokinetic parameters were determined using noncompartmental analysis. Endoscopic evaluation of the gastric mucosa was performed and serum urea nitrogen (SUN), creatinine, alkaline phosphatase (ALP), and alanine transaminase (ALT) activities were evaluated. There were not a clinically relevant difference between the pharmacokinetic parameters of piroxicam administered alone or in combination with cimetidine after either the first or last dose. Gastric ulcers were not observed in any cats although gastric erosions were. The SUN, creatinine, ALP, and ALT activities remained within reference ranges for all cats. It appears that once daily, short-term use of piroxicam alone and in combination with cimetidine in cats is relatively safe based on the parameters evaluated in this study. However, further studies are necessary to determine the long-term gastrointestinal safety of piroxicam.
Collapse
Affiliation(s)
- H L Heeb
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhanttan, KS, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Cárceles CM, Font A, Espuny A, Fernández-Varón E, Serrano JM, Escudero E. Pharmacokinetics of azithromycin after intravenous and intramuscular administration to goats. J Vet Pharmacol Ther 2005; 28:51-5. [PMID: 15720515 DOI: 10.1111/j.1365-2885.2004.00626.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Azithromycin is the first of a class of antimicrobial agents designated azalides. The aim of the present study was to investigate the disposition pharmacokinetics of azithromycin in goats and determine its bioavailability. A cross-over study was carried out in two phases separated by 30 days. Azithromycin was administered at a single dose of 20 mg/kg body weight by i.v. and i.m. routes. Plasma concentrations of azithromycin were determined by a modified agar diffusion bioassay. After a single i.v. dose plasma concentrations were best fitted to a three-compartment open model. A two-compartment open model with first-order absorption fitted best after i.m. administration. The values of the pharmacokinetic parameters after i.v. administration were: half-life 32.5 h, apparent volume of distribution at the steady-state 34.5 L/kg, clearance 0.85 L/kg. and mean residence time (MRT) 40.1 h. After i.m. administration half-life of 45.2 h, a MRT of 60.3 h, maximum plasma concentration 0.64 mg/L and a bioavalability 92.2% were obtained. The pharmacokinetic parameters of azithromycin after i.m. administration, principally its long half-life and high bioavailability, could provide an alternative to the oral route of administration in goats, although more studies are needed to establish a suitable pharmaceutical formulation, propose optimun dosage regimens, investigate clinical efficacy and study the tolerability of repeated doses.
Collapse
Affiliation(s)
- C M Cárceles
- Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Murcia, Spain
| | | | | | | | | | | |
Collapse
|
20
|
Koch DE, Bhandari A, Closb L, Hunter RP. Azithromycin extraction from municipal wastewater and quantitation using liquid chromatography/mass spectrometry. J Chromatogr A 2005; 1074:17-22. [PMID: 15941034 DOI: 10.1016/j.chroma.2005.03.052] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Azithromycin is a broad spectrum antimicrobial agent that is approved in the United States for use in humans. Due to azithromycin's low rate of metabolism it is likely to be found in wastewater treatment plants, where its broad spectrum of antimicrobial activity could lead to development of resistance in bacteria. A liquid-liquid extraction using K2CO3 and methyl-t-butyl ether (MTBE) was used to extract azithromycin from 10 ml aliquots of wastewater. Liquid chromatography was performed using a Luna C18(2) (30 mm x 2.0 mm) column with a mass spectrometer friendly mobile phase containing 50:24:2:24 acetonitrile, methanol, tetrahydrofuran, and 0.04 M ammonium hydroxide. The mass spectrometer used an electrospray source with positive ionization and an ion trap detector. A linear standard curve from 5 to 200pg/ml was validated and used to quantitate azithromycin in wastewater.
Collapse
Affiliation(s)
- David E Koch
- Zoological and Analytical Pharmacology Laboratory, Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
| | | | | | | |
Collapse
|
21
|
Owen WMA, Sturgess CP, Harbour DA, Egan K, Gruffydd-Jones TJ. Efficacy of azithromycin for the treatment of feline chlamydophilosis. J Feline Med Surg 2004; 5:305-11. [PMID: 14623199 DOI: 10.1016/s1098-612x(03)00072-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The current recommended treatment for feline chlamydophilosis involves daily oral administration of antimicrobials to all cats within an affected group for a prolonged period of time (4-6 weeks). Not surprisingly, owner compliance can be poor resulting in apparent treatment failure. Recent anecdotal evidence, supported by its efficacy in the treatment of Chlamydia trachomatis infection in humans, has suggested that azithromycin may offer an alternative by allowing less frequent dosing for a shorter duration. A clinical trial was designed to evaluate the efficacy of azithromycin for the treatment of chlamydia (Chlamydophila felis) infection in cats. Whilst azithromycin, given at 10-15 mg/kg daily for 3 days and then twice weekly, provided a similar, rapid resolution of clinical signs and negative isolation scores as doxycycline, C felis was re-isolated in four out of the five cats treated. Furthermore, even daily administration of azithromycin to chronically infected cats was ineffective in clearing infection. The azithromycin protocols used here were therefore found to be unsuccessful in eliminating the carriage of this strain of C felis.
Collapse
Affiliation(s)
- W M A Owen
- The Feline Centre, Department of Clinical Veterinary Science, University of Bristol, Langford House, Langford, Bristol BS40 5DU, UK.
| | | | | | | | | |
Collapse
|
22
|
Heeb HL, Chun R, Koch DE, Goatley MA, Hunter RP. Single dose pharmacokinetics of piroxicam in cats. J Vet Pharmacol Ther 2003; 26:259-63. [PMID: 12887607 DOI: 10.1046/j.1365-2885.2003.00479.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Piroxicam (PIRO) is a nonsteroidal anti-inflammatory drug (NSAID) recognized for its value as a chemopreventative and anti-tumor agent. Eight cats were included in this study. PIRO was administered in a single oral (p.o.) and intravenous (i.v.) dose of 0.3 mg/kg. The study was designed as a randomized complete crossover with a 2-week washout period. Serial blood samples were collected after each dose and plasma was analyzed for PIRO. Pharmacokinetic parameters of PIRO were determined using noncompartmental analysis. PIRO is well absorbed in the cat with a median bioavailability (F) of 80% (range 64-124%). The median i.v. t1/2 was 12 h (range 8.6-14 h). The median Cmax was 519 ng/mL with a corresponding Tmax of 3 h. PIRO appears to be rapidly absorbed following p.o. administration in cats with a higher Cmax and AUC than in dogs.
Collapse
Affiliation(s)
- H L Heeb
- Department of Clinical Sciences and; Department of Anatomy and Physiology, Kansas State University, College of Veterinary Medicine, Mosier Hall, Manhattan, KS 66506, USA.
| | | | | | | | | |
Collapse
|
23
|
Hunter RP, Koch DE, Coke RL, Goatley MA, Isaza R. Azithromycin metabolite identification in plasma, bile, and tissues of the ball python (Python regius). J Vet Pharmacol Ther 2003; 26:117-21. [PMID: 12667181 DOI: 10.1046/j.1365-2885.2003.00464.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Azithromycin is the first of a class of antibiotics classified as azalides. Six ball pythons (Python regius) were given a single dose of azithromycin at 10 mg/kg p.o. and i.v. in a crossover design. Serial blood samples were collected for unchanged azithromycin and to determine, if possible, the structure and number of circulating azithromycin metabolites. After a 4-month wash-out period, the snakes were given azithromycin p.o. as a single dose of 10 mg/kg for the study of azithromycin metabolism and metabolite tissue distribution. Bile, liver, lung, kidney, and skin samples were analyzed for the metabolites identified from the first experiment. Unchanged azithromycin accounted for 80, 68, and 60% of the total material at 12, 24, and 48 h postadministration in plasma, independent of route of administration. At both 24 and 72 h postadministration, azithromycin accounted for 70% of total azithromycin- associated material in bile. In liver and kidney, unchanged azithromycin accounted for 40% of the total azithromycin-associated material; this doubled in lung and skin. Fifteen metabolites were positively or tentatively identified in plasma, bile, or tissues of all snakes. Four of these possible metabolites: 3'-desamine-3-ene-azithromycin, descladinose dehydroxy-2-ene-azithromycin, 3'-desamine-3-ene descladinose-azithromycin, and 3'-N-nitroso,9a-N-desmethyl-azithromycin are unique to this species. Descladinose-azithromycin, 3'-N-desmethyl,9a-N-desmethyl-azithromycin, and 3'-N-desmethyl, 3'-O-desmethyl-azithromycin were the only metabolites identified in skin. Kidney tissue contained a greater number of metabolites than liver tissue, with 3'-N-didesmethyl-azithromycin being identified only in the kidney. Compared with the dog and cat, a greater number of metabolites were identified in ball python plasma. The percentage of unchanged azithromycin in bile is not different between the three species.
Collapse
Affiliation(s)
- R P Hunter
- Department of Anatomy and Physiology, Zoological Pharmacology Laboratory, Kansas State University, Manhattan 66506, USA.
| | | | | | | | | |
Collapse
|
24
|
Coke RL, Hunter RP, Isaza R, Koch DE, Goatley MA, Carpenter JW. Pharmacokinetics and tissue concentrations of azithromycin in ball pythons (Python regius). Am J Vet Res 2003; 64:225-8. [PMID: 12602593 DOI: 10.2460/ajvr.2003.64.225] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine pharmacokinetics and tissue concentrations of azithromycin in ball pythons (Python regius) after IV or oral administration of a single dose. ANIMALS 2 male and 5 female ball pythons. PROCEDURES Using a crossover design, each snake was given a single dose of azithromycin (10 mg/kg) IV. After a 4-week washout period, each snake was given a single dose of azithromycin (10 mg/kg) orally. Blood samples were collected prior to dose administration and 1, 3, 6, 12, 24, 48, 72, and 96 hours after azithromycin administration. Azithromycin was quantitated by use of liquid chromatography-mass spectrometry. RESULTS After IV administration, azithromycin had an apparent volume of distribution of 5.69 L/kg and a plasma clearance of 0.19 L/h/kg. Harmonic means for the terminal half-life were 17 hours following IV administration and 51 hours following oral administration. Mean residence times were 37 and 94 hours following IV and oral administration, respectively. Following oral administration, azithromycin had a peak plasma concentration (Cmax) of 1.04 microg/mL, a time to Cmax of 8.4 hours, and a prolonged mean absorption time of 57 hours. Mean oral bioavailability was 77%. Tissue concentrations ranged from 4 to 140 times the corresponding plasma concentration at 24 and 72 hours after azithromycin administration. CONCLUSIONS AND CLINICAL RELEVANCE Azithromycin is well absorbed and tolerated by ball pythons. On the basis of plasma pharmacokinetics and tissue concentration data, we suggest an azithromycin dosage in ball pythons of 10 mg/kg, orally, every 2 to 7 days, depending upon the site of infection and susceptibil ity of the infective organism.
Collapse
Affiliation(s)
- Rob L Coke
- Zoological Pharmacology Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
| | | | | | | | | | | |
Collapse
|
25
|
Davis JL, Gardner SY, Jones SL, Schwabenton BA, Papich MG. Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes. J Vet Pharmacol Ther 2002; 25:99-104. [PMID: 12000529 DOI: 10.1046/j.1365-2885.2002.00387.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The properties of azithromycin suggest that it may be an alternative to erythromycin for treatment of Rhodococcus equi pneumonia in foals. To investigate this possibility, the disposition of azithromycin in plasma, polymorphonuclear leukocytes (PMN), and alveolar cells was examined after a single administration in foals. Azithromycin suspension was administered orally (p.o.) at a dose of 10 mg/kg to five healthy 2-3-month-old foals. Two weeks later, azithromycin for injection was administered by intravenous (i.v.) infusion at a dose of 5 mg/kg to the same foals. Plasma samples were collected after p.o. and i.v. administration. Peripheral blood PMN and bronchoalveolar lavage fluid and alveolar cells were collected after p.o. administration. Azithromycin concentrations were determined by reverse-phase high-performance liquid chromatography (HPLC) with coulometric electrochemical detection. Azithromycin p.o. absorption was variable with a mean systemic availability of 39% (+/-20%). The plasma half-life was 16 and 18.3 h after i.v. and p.o. administration, respectively. Azithromycin had a very large volume of distribution (V(d)) of 11.6 L/kg [V(d(ss))] and 12.4 L/kg [V(d(area))]. The large V(d) can be attributed to high tissue and intracellular concentrations, exhibited by the high concentration of azithromycin in PMN and alveolar cells. The PMN half-life was 49.2 h. Dosage of 10 mg/kg of azithromycin p.o. once daily for foals with R. equi pneumonia is recommended for further study.
Collapse
Affiliation(s)
- J L Davis
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina 27606, USA
| | | | | | | | | |
Collapse
|
26
|
Westfall DS, Jensen WA, Reagan WJ, Radecki SV, Lappin MR. Inoculation of two genotypes of Hemobartonella felis (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin. Am J Vet Res 2001; 62:687-91. [PMID: 11341386 DOI: 10.2460/ajvr.2001.62.687] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To describe clinical and laboratory findings associated with cats experimentally infected by inoculation with the 2 recognized genotypes of Hemobartonella felis (small variant, Hfsm; large variant, Hflg) and to determine the response of cats to treatment with azithromycin. ANIMALS 18 young adult domestic shorthair cats of both sexes. PROCEDURES Cats were inoculated with H felis and monitored weekly, using CBC counts and a polymerase chain reaction (PCR) designed to detect both genetic variants of H felis. Beginning 26 days after inoculation, 11 cats were administered azithromycin (15 mg/kg of body weight, PO, q 12 h, for 7 days). RESULTS Inoculation resulted in coinfection with Hflg and Hfsm, and both variants were detected by PCR. Clinical abnormalities and anemia were most severe in Hflg- and dual-infected cats. Results of PCR and CBC were positive for H felis in 112/112 (100%) and 42/112 (37.5%), respectively, samples collected after inoculation. Administration of azithromycin had little effect on clinical variables, including anemia. All cats, regardless of treatment with azithromycin, had positive results for the PCR at the end of the study period. CONCLUSIONS AND CLINICAL RELEVANCE In these cats, Hflg was more pathogenic than Hfsm, and coinfection with both variants was detected. Results of the PCR were superior to results of CBC for detecting infection with H felis. Azithromycin administered at the dose and duration reported here was not efficacious for the treatment of cats with hemobartonellosis.
Collapse
Affiliation(s)
- D S Westfall
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523, USA
| | | | | | | | | |
Collapse
|
27
|
Mandelker L. Experimental drug therapy for respiratory disorders in dogs and cats. Vet Clin North Am Small Anim Pract 2000; 30:1357-67, viii. [PMID: 11221986 DOI: 10.1016/s0195-5616(00)06011-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Experimental therapy in veterinary medicine is based on empiric reasoning. If a particular therapy is labeled experimental, it means that its effectiveness has not been demonstrated scientifically. Empiric therapy is experimental and is based on experience, not on scientific proof. The purpose of this article is to suggest the use of specific experimental drug therapies for certain respiratory disorders in dogs and cats.
Collapse
|
28
|
Malik R, Wigney DI, Dawson D, Martin P, Hunt GB, Love DN. Infection of the subcutis and skin of cats with rapidly growing mycobacteria: a review of microbiological and clinical findings. J Feline Med Surg 2000; 2:35-48. [PMID: 11716590 DOI: 10.1053/jfms.2000.0051] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Mycobacteria were isolated and characterised from 49 cats with extensive infections of the subcutis and skin. Cats were generally between 3 and 10 years of age, and female cats were markedly over-represented. All isolates were rapid-growers and identified as either Mycobacteria smegmatis (40 strains) or M fortuitum (nine strains). On the basis of Etest for minimum inhibitory concentration and/or disc diffusion susceptibility testing, all strains of M smegmatis were susceptible to trimethoprim while all strains of M fortuitum were resistant. M smegmatis strains were typically susceptible to doxycycline, gentamicin and fluoroquinolones but not clarithromycin. All M fortuitum strains were susceptible to fluoroquinolones, and often also susceptible to gentamicin, doxycycline and clarithromycin. Generally, M smegmatis strains were more susceptible to antimicrobial agents than M fortuitum strains. Treatment of mycobacterial panniculitis involves long courses of antimicrobial agents, typically of 3-6 months, chosen on the basis of in vitro susceptibility testing and often combined with extensive surgical debridement and wound reconstruction. These therapies will result in effective cure of the disease. One or a combination of doxycycline, ciprofloxacin/enrofloxacin or clarithromycin are the drugs of choice for long-term oral therapy.
Collapse
Affiliation(s)
- R Malik
- Department of Veterinary Clinical Sciences, The University of Sydney, New South Wales, Australia 2006.
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
This article discusses several different new drugs currently being used in dermatology. Most of the drugs discussed showed some promise as being a useful therapy in veterinary medicine, but a few have questionable efficacy (nonsedating antihistamines). The majority of these drugs have not had any pharmacokinetic or clinical trials conducted on them in small animals. Hopefully, in the future, more studies are funded so that we can determine the clinical therapeutical efficacy and appropriate doses for these drugs.
Collapse
Affiliation(s)
- C A Rees
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, Texas A&M University, College Station, USA
| |
Collapse
|
30
|
|
31
|
Abstract
Mycoplasma spp were isolated in pure culture from bronchoalveolar lavage specimens from three cats with clinical, cytological and radiographic signs of bronchopneumonia or suppurative bronchitis. Predisposing factors were not identified in the first case, the second cat had oesophageal hypomotility, while the third cat had been exposed to cigarette smoke and had advanced periodontal disease. Respiratory signs resolved promptly and completely in all cases following antimicrobial therapy directed against mycoplasmas. Mycoplasma spp are possible causes of lower respiratory tract disease in cats and this should be considered when selecting empirical therapy for feline airway disease and pneumonia. In some situations mycoplasmas may behave as primary lower respiratory tract pathogens in cats.
Collapse
Affiliation(s)
- S F Foster
- Department of Veterinary Clinical Sciences, University of Sydney, New South Wales
| | | | | | | |
Collapse
|
32
|
Abstract
This article will focus on the drugs for which there has been a recent or renewed interest in veterinary medicine. Some of these are new drugs that were recently introduced. Others discussed may be human-label drugs for which there has been recent interest in veterinary medicine because of the need for a more active drug or convenient regimen. For drugs such as the aminoglycosides included here, recent information has provided us with updated dosage guidelines.
Collapse
Affiliation(s)
- M G Papich
- Department of Anatomy, Physiological Sciences, and Radiology, College of Veterinary Medicine, North Carolina State University, Raleigh, USA.
| |
Collapse
|